TCA
ABBV icon

Transcend Capital Advisors’s AbbVie ABBV Stock Holding History

Transcend Capital Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.19M Sell
28,467
-961
-3% -$213K 0.5% 39
2025
Q4 		$6.72M Sell
29,428
-3,328
-10% -$758K 0.52% 37
2025
Q3 		$7.58M Sell
32,756
-5,623
-15% -$1.15M 0.53% 39
2025
Q2 		$7.12M Sell
38,379
-3,798
-9% -$706K 0.55% 39
2025
Q1 		$8.84M Sell
42,177
-883
-2% -$172K 0.63% 33
2024
Q4 		$7.65M Sell
43,060
-3,303
-7% -$607K 0.55% 39
2024
Q3 		$9.16M Buy
46,363
+136
+0.3% +$25.4K 0.61% 35
2024
Q2 		$7.93M Buy
46,227
+17,559
+61% +$2.91M 0.58% 35
2024
Q1 		$5.22M Buy
28,668
+6,775
+31% +$1.17M 0.42% 51
2023
Q4 		$3.39M Sell
21,893
-256
-1% -$37.3K 0.3% 79
2023
Q3 		$3.3M Sell
22,149
-246
-1% -$36.1K 0.32% 71
2023
Q2 		$3.02M Buy
22,395
+339
+2% +$49.7K 0.29% 84
2023
Q1 		$3.52M Sell
22,056
-415
-2% -$63.4K 0.37% 59
2022
Q4 		$3.63M Sell
22,471
-654
-3% -$100K 0.39% 57
2022
Q3 		$3.1M Buy
23,125
+132
+0.6% +$18.9K 0.34% 72
2022
Q2 		$3.52M Sell
22,993
-343
-1% -$52.4K 0.37% 63
2022
Q1 		$3.78M Buy
23,336
+813
+4% +$118K 0.34% 71
2021
Q4 		$3.05M Buy
22,523
+623
+3% +$73.6K 0.27% 98
2021
Q3 		$2.4M Buy
21,900
+2,626
+14% +$300K 0.21% 108
2021
Q2 		$2.17M Buy
19,274
+1,430
+8% +$161K 0.31% 86
2021
Q1 		$1.94M Sell
17,844
-607
-3% -$64.9K 0.23% 111
2020
Q4 		$1.98M Buy
18,451
+2,858
+18% +$275K 0.26% 102
2020
Q3 		$1.37M Buy
15,593
+1,240
+9% +$117K 0.25% 94
2020
Q2 		$1.41M Sell
14,353
-3,494
-20% -$308K 0.46% 65
2020
Q1 		$1.36M Sell
17,847
-842
-5% -$71.7K 0.41% 75
2019
Q4 		$1.66M Buy
+18,689
New +$1.55M 0.45% 71

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Transcend Capital Advisors's ABBV Position: Q1 2026 in Review

Transcend Capital Advisors reduced its AbbVie (ABBV) stake by 3.3% in Q1 2026, selling an estimated $213K and leaving 28,467 shares worth $6.19M. The position accounts for 0.5% of the portfolio, ranked #39.

Transcend Capital Advisors first reported a position in ABBV in Q4 2019 and has held it in 26 quarters since. The position peaked at $9.16M in Q3 2024. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Transcend Capital Advisors held 28,467 shares of AbbVie worth $6.19M as of Q1 2026.
  • Transcend Capital Advisors sold 961 AbbVie shares in Q1 2026, an estimated $213K.
  • AbbVie made up 0.5% of Transcend Capital Advisors's portfolio in Q1 2026, its #39 holding.
  • Transcend Capital Advisors first reported a position in AbbVie in Q4 2019 and has held it in 26 quarters since.
  • Transcend Capital Advisors's AbbVie position peaked at $9.16M in Q3 2024.
  • 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Transcend Capital Advisors's 13F filing for Q1 2026, filed 13 May 2026.